FIELD: medicine.
SUBSTANCE: invention refers to medicine, specifically to pharmacology, and concerns an agent having an effect on cardiovascular system. The agent contains acetylsalicylic acid and succinic acid or its pharmaceutically acceptable salt in the ratio, weight parts: 1:20-20:1. The agent can be used for treatment of various forms of coronary heart disease (CHD), acute myocardial infarction, coronary insufficiency, cerebral ischemia, hypoxic stroke.
EFFECT: invention provides extended range of the agents possessing cardioprotective, antiarrhythmic and anti-ischemic action.
2 cl, 5 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
NATURAL PHOSPHOLIPID AGENT | 2008 |
|
RU2367443C1 |
2-[2-(DIETHYLAMINO) -ETHYLTHIO]-5,6- DIMETHYLBENZIMIDAZOLE SALTS SHOWING ANTIISCHEMIC, ANTIHYPOXIC AND ANTIARRHYTHMIC ACTIVITY AND 2-[2-(DIETHYLAMINO) -ETHYLTHIO]-5,6- DIMETHYLBENZIMIDAZOLE AS AN INTERMEDIATE PRODUCT FOR SYNTHESIS OF 2-[2-(DIETHYLAMINO) -ETHYLTHIO] -5,6-DIMETHYLBENZIMIDAZOLE SALTS | 1991 |
|
RU2027709C1 |
COMBINED DRUG PREPARATION CARDIFOL EXHIBITING CARDIOPROTECTIVE, ANTIAGGREGANT AND ANTI-ISCHEMIC ACTION ON CARDIOVASCULAR SYSTEM | 2011 |
|
RU2446806C1 |
METHOD OF BRAIN MITOCHONDRIA PREPARATION | 0 |
|
SU1745258A1 |
AGENT POSSESSING ENDOTHELIUM PROTECTIVE ACTIVITY | 2014 |
|
RU2563622C1 |
CARDIOPROTECTIVE AND ANTIARRHYTHMIC MEDICINE | 2022 |
|
RU2783444C1 |
ORGANIC SALTS N1-(2,3,4-TRIMETHOXYBENZYL)-N2-{2-[(2,3,4-TRIMETHOXYBENZYL)AMINO]ETHYL}-1,2-ETHANE-DIAMINE | 2022 |
|
RU2813347C2 |
COMBINED DRUG FOR PRIMARY NEUROPROTECTION | 2017 |
|
RU2636616C1 |
GAMMA-HYDROXYPROPYLAMMONIUM-5-HYDROXYNICOTINATE ELICITING ANTI-ISCHEMIC, ANTI-ARRHYTHMIC AND HYPOLIPIDEMIC ACTIVITY | 2003 |
|
RU2245329C1 |
COMBINED ANTIAGGREGANT AND ANTIOXIDANT | 2010 |
|
RU2430728C1 |
Authors
Dates
2009-09-10—Published
2007-07-02—Filed